文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒特殊人群用药

儿童伏立康唑血药浓度与不良反应关系的影响因素分析

Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population.
PubMed 文献 · Br J Clin Pharmacol · 2025-02-25

本研究纳入2020至2022年日本儿童患者60例,分析伏立康唑血药浓度与不良反应的关系。

要点

  • 儿童伏立康唑不良反应者血药浓度显著高于无不良反应者。
  • CYP2C19*2或*3携带者血药浓度有升高趋势但未达统计学显著。
  • 纳入CYP2C19携带状态的模型预测不良反应AUC为0.70。

核心结论

  • CYP2C19多态性在伏立康唑诱导的儿童血小板减少和胆汁淤积中起作用。

研究设计与样本

  • 研究纳入2020至2022年日本儿童患者60例,平均年龄6.5岁,53.3%为男性。
  • 采用群体药代动力学方法建模伏立康唑血药浓度,缺失值用贝叶斯法在Phoenix NLME中估计。
  • 分析CYP2C19*2、*3和*17,收集用药前后临床和实验室数据。

主要发现

  • 60例中38例血液恶性肿瘤、18例先天性免疫缺陷、2例实体瘤、2例其他疾病。
  • 预测模型纳入CYP2C19*2或*3携带状态、C反应蛋白和血小板计数,总方差解释23.6%,其中携带状态单独解释2.6%。
  • 纳入携带状态后预测不良反应的ROC曲线下面积为0.70。

临床怎么用

  • 儿童使用伏立康唑时应关注血药浓度,尤其出现血小板减少或胆汁淤积时。
  • CYP2C19*2或*3携带状态可辅助评估不良反应风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The influence of CYP2C19 polymorphisms on voriconazole plasma concentrations is recognized, but its extent, other contributing factors and risks for adverse reactions remain under-explored. METHODS: This study focused on Japanese paediatric patients recruited between 2020 and 2022 treated with voriconazole. We specifically investigated the occurrence of cholestasis and thrombocytopenia as adverse reactions of voriconazole. Voriconazole plasma levels were modelled in a previous study using a population pharmacokinetics approach. Missing values were estimated with a Bayesian method in Phoenix NLME. We analysed CYP2C19*2, CYP2C19*3 and CYP2C19*17. Clinical and laboratory data were collected before and after voriconazole treatment. RESULTS: Among the 60 patients (mean age: 6.5 years; 53.3% male), 38 had haematological malignancies, 18 inborn errors of immunity, 2 solid tumours and 2 other diseases. Adverse reactions occurred in 12 patients. The voriconazole plasma concentrations were significantly higher in those experiencing these adverse reactions (mean normalized concentrations: 0.66 in cases vs. -0.16 in controls, P = .025), with a trend towards higher concentrations in carriers of the CYP2C19*2 or *3 alleles (mean normalized concentrations: 0.98 in carrier cases vs. 0.016 in noncarrier cases, P = .14). A predictive model for voriconazole concentrations, incorporating carriership of CYP2C19*2 or *3, C-reactive protein levels, and platelet counts, showed a summed variance explained of 23.6% with the variance attributable to CYP2C19*2 or *3 carrier status alone was 2.6%. Including carrier status improved the area under the receiver operating characteristic curve for predicting adverse reactions to 0.70. CONCLUSIONS: Our findings underscore the role of the CYP2C19 polymorphism in voriconazole-induced thrombocytopenia and cholestasis.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Hikino K, Shoji K, Saito J, et al. Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population. Br J Clin Pharmacol. 2025. PMID: 40001258. doi:10.1002/bcp.70026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。